Examining the Challenges of Donanumab Treatment for Early Alzheimer’s Disease

This chapter explores the financial challenges associated with donanumab treatment for early Alzheimer's disease, including high costs and insurance hurdles. It also compares donanumab with alternative oral treatments in terms of expense, administration, and effectiveness.